Study guide
10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes
Key Takeaways Explain This Topic AI
An OECD AOP is a chemical-agnostic causal sequence from a molecular initiating event (MIE) through measurable key events (KEs) linked by key event relationships (KERs) to an adverse outcome (AO) used in risk or regulatory decisions.
MOA is chemical-specific (including that chemical’s ADME); an AOP is modular and stressor-agnostic—any stressor that triggers the MIE can travel the pathway if potency and duration suffice.
AOP-Wiki is the OECD-supported knowledge base; handbook 2.8 (2026) is the developers’ handbook. Wiki status ranges from under development to reviewed or endorsed—an entry is not automatically an OECD-adopted test guideline.
Essentiality (block a KE and downstream events fail), biological plausibility of KERs, and empirical dose/incidence/temporal support are the weight-of-evidence tools for an AOP.
Integrated approaches to testing and assessment (IATA) use AOPs to choose which KEs to measure; defined approaches (for example OECD 497 skin sensitization) are fixed recipes of information sources plus a data-interpretation procedure inside that umbrella.
Last updated: September 2026
Why AOPs are a Domain II.4 companion to MOA
Section 10.1 evaluated a chemical-specific MOA . Handbook II.4 also expects you to follow a perturbation from a molecular interaction to organ-level and organism outcomes. The Organisation for Economic Co-operation and Development (OECD) adverse outcome pathway (AOP) is the shared vocabulary for that sequence when you are not tying it to one substance’s metabolism. Independent ExamFinch teaching in this section covers OECD AOP architecture, AOP-Wiki as a knowledge base, modularity , and how AOPs structure integrated approaches to testing and assessment (IATA) . It is not an OECD, AOP-Wiki, or ABT product and does not claim official approval, review, or partnership with those bodies.
An AOP starts with a molecular initiating event (MIE) : the initial chemical/stressor interaction with a biomolecule that perturbs biology (covalent protein haptenation; receptor agonism; acetylcholinesterase serine phosphorylation; DNA adduct formation). It proceeds through intermediate key events (KEs) —measurable, essential changes in biological state—and ends in an adverse outcome (AO) that matters for risk assessment or a regulatory decision (allergic contact dermatitis; hepatocellular carcinoma; population-level reproductive failure in fish). Key event relationships (KERs) are the causal, predictive links: if the upstream KE is in a given state, what can you infer about the downstream KE?
The AOP Developers’ Handbook (version 2.8 , March 2026 , succeeding the older “Users’ Handbook”) sits beside OECD ENV/JM/MONO(2013)6 . You are not asked to author a wiki page on the examination. You are asked to use the nouns correctly and to know that an AOP is not a complete PBPK model, not a full chemical risk assessment, and not a claim that every chemical hitting the MIE will reach the AO. Severity, duration, ADME, repair, and modulating factors decide whether the cascade runs.
MIE, KEs, KERs, and AO
MIE. Specialized KE at the molecular interaction. It is still a KE: it must be measurable in principle (peptide reactivity, receptor occupancy, enzyme inhibition). “Oxidative stress” as a vague cloud is a poor MIE; “covalent binding to cysteine thiols on skin proteins” is a usable MIE.
KE. A change that is essential to progression toward that AO. Essentiality is tested when you can block the KE (knockout, antagonist, recovery) and the downstream events weaken or disappear. A correlative omics node that can be bypassed is a modulating factor , not a KE. Chapter 8’s warning still holds: an Nrf2 transcript without dysfunction is not an AO.
KER. Captures biological plausibility (does physiology allow upstream to drive downstream?) and empirical support (dose–response, incidence, temporal concordance—the same Hill-type ideas as MOA, now applied to a pair of events). Quantitative KERs (how much KE1 produces how much KE2) are the prize for predictive toxicology; many AOPs are still qualitative.
AO. An apical effect used in a decision: organism disease, death, or an ecological endpoint such as impaired reproduction or population decline. Organ-level outcomes (follicular-cell hyperplasia; centrilobular necrosis) often sit as late KEs immediately before the AO. Do not stop the pathway at a convenient in vitro readout and call that the AO unless the decision problem truly is that readout.
The simple teaching chain is MIE → KE1 → KE2 → AO . Real AOPs may have more KEs. The OECD skin sensitization AOP, the cleanest regulatory example, is often listed as protein haptenation (MIE), keratinocyte inflammatory responses, dendritic-cell activation, T-cell priming/proliferation, then allergic contact dermatitis. The diagram below compresses the cellular immune KEs so you can see the four-box shape the examination stem will draw.
Modularity and AOP networks
KEs and KERs are modular . The same “Sustained AhR activation” KE can feed more than one AO. The same “hepatocyte death” KE can sit downstream of different MIEs (reactive metabolite versus BSEP inhibition). AOP networks are those shared nodes drawn together. Modularity is why you do not rewrite biology from scratch for every CAS number: you reuse KE descriptions and point a new chemical at the MIE it actually hits.
Modularity is also a trap. Sharing a KE does not mean two chemicals share potency, ADME, or even the same AO mix. A chemical can launch several AOPs at once (a sensitizer that is also a mutagen). An AOP does not encode first-pass extraction; that still lives in the chemical-specific MOA and in PBPK.
AOP-Wiki, conceptually
AOP-Wiki (aopwiki.org) is the collaborative knowledge base that supports the OECD AOP development programme. Release 2.8 of the wiki and handbook landed in March 2026 . Entries typically include prototypical stressors (examples that illustrate the MIE, not an exhaustive chemical list), KE and KER pages that can be reused, and a status that may be under development, internally reviewed, or further along toward OECD endorsement. Browsing a page is not the same as citing an OECD Test Guideline. Many living entries are hypotheses with incomplete essentiality data. Examination skill: use Wiki vocabulary; do not treat every page as adopted regulatory text.
Prototypical stressors help teaching (2,4-dinitrochlorobenzene for sensitization haptenation; a named AChE inhibitor for cholinergic AOPs). They do not convert the AOP into a chemical-specific MOA. If the stem names a chemical, you still need that chemical’s metabolism, route, and potency to say whether it will traverse the AOP.
MOA (chemical-specific) versus AOP (chemical-agnostic)
This contrast is high-yield.
- Feature Mode of action (MOA) Adverse outcome pathway (AOP)
- Chemical identity Specified (or a tight analogue set) Agnostic: any stressor that triggers the MIE
ADME / bioactivation Part of the story for that molecule Generally outside the AOP; handled when a chemical is mapped onto the MIE
Building blocks Key events for that chemical’s apical effect MIE, KEs, KERs, AO; reusable modules
Typical use Human-relevance and low-dose family for a dossier Testing strategy, category formation, IATA design
Success test Bradford Hill-type concordance for that chemical in a species Essentiality and KER evidence that the biology is general
A chemical’s MOA may instantiate one or more AOPs plus ADME. Phenobarbital-type thyroid tumors: the AOP is “increased hepatic TH clearance → ↓T4 → ↑TSH → follicular proliferation → tumors.” The MOA for phenobarbital adds CAR activation, which UGTs are induced, rat versus human TBG, and the human-relevance call from section 10.1. Do not call the AOP “not relevant to humans” as a property of the pathway diagram; relevance is a species and chemical mapping problem.
How AOPs inform testing strategies and IATA
IATA (OECD Series on Testing and Assessment, including No. 260 on using AOPs to develop IATA) is a pragmatic, problem-driven integration of existing information with new tests chosen because they query named KEs. You start with the decision (skin sensitizer: yes/no/potency; endocrine activity; aquatic reproductive hazard), map data gaps onto KEs, and run the smallest set of methods that can fill those gaps—in silico, in chemico, in vitro, then targeted in vivo if still needed. IATA still allows expert judgment in how streams are combined.
A defined approach (DA) is stricter: a fixed set of information sources and a fixed data interpretation procedure (DIP) . OECD Test Guideline 497 defined approaches for skin sensitization are the working example. Non-animal methods map onto early KEs: OECD 442C (peptide/protein binding, MIE), 442D (keratinocyte activation), 442E (dendritic-cell activation). Individual assays are generally not stand-alone replacements for classification; the DA’s DIP (for example a 2-out-of-3 hazard call, or an integrated testing strategy that adds in silico potency) is what yields a prediction inside the stated applicability domain. Chapter 6 taught LLNA EC3, guinea-pig tests, and when pharmaceuticals run these packages. Here the point is architectural: the AOP tells you which KE each assay is for , so you do not treat a keratinocyte reporter as a full animal LLNA or as a mutagenicity test.
Other testing-strategy uses: grouping chemicals that share an MIE; choosing a fish vitellogenin or aromatase assay because an endocrine AOP says that KE sits on the path to impaired reproduction; skipping a two-year bioassay question that an established non-genotoxic AOP plus IATA already frames as a different study type. AOPs also support read-across when analogues share an MIE and you can argue they will reach it in vivo—without pretending read-across is automatic.
Scenario
A new acrylate for a dermal adhesive is peptide-reactive (442C positive), activates a keratinocyte reporter (442D positive), and is negative in a dendritic-cell assay (442E) at soluble concentrations. A 2-out-of-3 DA may still call a sensitizer hazard if two KEs are positive and the chemical sits in domain; a single negative KE does not erase the MIE. The AOP does not tell you workplace airborne concentration. That is exposure assessment (chapter 11).
A second file is an organophosphate. The AOP (AChE inhibition → acetylcholine excess → cholinergic AO) is chemical-agnostic. The MOA for that OP still needs aging versus reactivation, whether neuropathy-target esterase is also inhibited, and species cholinesterase differences. Treating every insecticide as this AOP was the chapter 9 class error; treating this AOP as a full chemical risk assessment is the chapter 10 error.
A third file cites an AOP-Wiki page “under development” with no essentiality data as if it were OECD 497. The pathway is a hypothesis . It can still guide a literature search; it cannot, by itself, replace a required apical study without an accepted IATA/DA and a defined decision context.
Traps
Calling an AOP chemical-specific, or calling a MOA chemical-agnostic.
Treating every AOP-Wiki page as an endorsed test guideline.
Equating a single KE assay with the AO.
Forgetting ADME when mapping a chemical onto an MIE (a potent in chemico hapten that is instantly hydrolyzed in blood may never reach skin proteins in vivo).
Using IATA and defined approach as synonyms: DAs are fixed recipes; IATA can include expert integration.